Bone Marrow Immune Signatures in Multiple Myeloma Are Linked to Tumor Heterogeneity and Treatment Outcome
Simon Steiger(German Cancer Research Center), Marc S. Raab(Unknown), Katharina Kriegsmann(Getrag (Germany)), Philipp Reichert(Heidelberg University), Anna Jauch, Katja Weisel(Universität Hamburg), Stephan M. Tirier(German Cancer Research Center), Stefanie Huhn(Heidelberg University), Sabrina Schumacher(German Cancer Research Center), Carsten Müller‐Tidow(Heidelberg University), Simon Haas(German Cancer Research Center), Alexandra M. Poos(German Cancer Research Center), Roland Schroers(University Hospitals of the Ruhr-University of Bochum), Florian Grünschläger(German Cancer Research Center), Diana Tichy(German Cancer Research Center), Niels Weinhold(German Cancer Research Center), Britta Besemer(Centre Hospitalier Universitaire de Nantes), Hartmut Goldschmidt(Heidelberg University), Subarna Palit(Munich University of Applied Sciences), Nadine Hefner(Heidelberg University), Jan‐Philipp Mallm(German Cancer Research Center), Mohamed H.S. Awwad(Heidelberg University), Karsten Rippe(German Cancer Research Center), Uta Bertsch(Heidelberg University), Hans Salwender(Asklepios Klinik Altona), Nina Prokoph(MRC Laboratory of Molecular Biology), Dominik Vonficht, Raphael Lutz(German Cancer Research Center), Anja Baumann(University of Vienna), Mirco Friedrich(Broad Institute), Michael Hundemer(Heidelberg University), Laleh Haghverdi(Max Delbrück Center), Roland Fenk(Beth Israel Deaconess Medical Center), Lukas John(University of Hohenheim)
Cited by 4
Related Papers
Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group
|Journal of Clinical Oncology|2015|2.2k
Teclistamab in Relapsed or Refractory Multiple Myeloma
|New England Journal of Medicine|2022|1.2k
A cellular census of human lungs identifies novel cell states in health and in asthma
|Nature Medicine|2019|966
Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study
|Leukemia|2011|721
International myeloma working group consensus recommendations on imaging in monoclonal plasma cell disorders
|The Lancet Oncology|2019|493